The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
Open accessAbstract
IMPORTANCE: Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking. OBJECTIVE: To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis. DESIGN, SETTING, AND PARTICIPANTS: Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Data were stratified by subtype, age, sex, and race. Multivariable logistic and Cox regression were performed to identify predictors of the presence of brain metastases at diagnosis and factors associated with all-cause mortality, respectively. For incidence, we identified a population-based sample of 238 726 adult patients diagnosed as having invasive breast cancer between 2010 and 2013 for whom the presence or absence of brain metastases at diagnosis was known. Patients diagnosed at autopsy or with an unknown follow-up were excluded from the survival analysis, leaving 231 684 patients in this cohort. MAIN OUTCOMES AND MEASURES: Incidence proportion and median survival of patients with brain metastases and newly diagnosed breast cancer. RESULTS: We identified 968 patients with brain metastases at the time of diagnosis of breast cancer, representing 0.41% of the entire cohort and 7.56% of the subset with metastatic disease to any site. A total of 57 were 18 to 40 years old, 423 were 41 to 60 years old, 425 were 61-80 years old, and 63 were older than 80 years. Ten were male and 958 were female. Incidence proportions were highest among patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (1.1% among entire cohort, 11.5% among patients with metastatic disease to any distant site) and triple-negative (0.7% among entire cohort, 11.4% among patients with metastatic disease to any distant site) subtypes. Median survival among the entire cohort with brain metastases was 10.0 months. Patients with HR-positive HER2-positive subtype displayed the longest median survival (21.0 months); patients with triple-negative subtype had the shortest median survival (6.0 months). CONCLUSIONS AND RELEVANCE: The findings of this study provides population-based estimates of the incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer. The findings lend support to consideration of screening imaging of the brain for patients with HER2-positive or triple-negative subtypes and extracranial metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.149 · Cited by 1,843
Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Barker, F. G., Deming, R., Burri, S. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.9839 · Cited by 1,671
Schouten, L. J., Rutten, J., Huveneers, H. A. M., & Twijnstra, A. (2002) · Cancer · doi:10.1002/cncr.10541 · Cited by 1,590
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Marital Status and Survival in Patients With Cancer
Aizer, A. A., Chen, M.-H., McCarthy, E. P., Mendu, M. L., Koo, S., Wilhite, T. J., Graham, P. L., Choueiri, T. K., Hoffman, K. E., Martin, N. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6489 · Cited by 1,031
Self-citationLin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Self-citationLin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y., Blayney, D. W., Niland, J. C., Winer, E. P., & Weeks, J. C. (2012) · Cancer · doi:10.1002/cncr.27581 · Cited by 695
Self-citationSoffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0639 · Cited by 636
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
Breast carcinoma: Pattern of metastasis at autopsy
Lee, Y. N. (. (1983) · Journal of Surgical Oncology · doi:10.1002/jso.2930230311 · Cited by 406
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Clayton, A. J., Danson, S., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R. S., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 385
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.08.009 · Cited by 338
Lack of reduction in racial disparities in cancer‐specific mortality over a 20‐year period
Aizer, A. A., Wilhite, T. J., Chen, M., Graham, P. L., Choueiri, T. K., Hoffman, K. E., Martin, N. E., Trinh, Q., Hu, J. C., & Nguyen, P. L. (2014) · Cancer · doi:10.1002/cncr.28617 · Cited by 252
Self-citationMiller, K. D., Weathers, T., Haney, L. G., Timmerman, R., Dickler, M., Shen, J., & Sledge Jr, G. W. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg300 · Cited by 244
Swain, S. M., Baselga, J., Miles, D., Im, Y.-H., Quah, C., Lee, L. F., & Cortés, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu133 · Cited by 232
Sihto, H., Lundin, J., Lundin, M., Lehtimäki, T., Ristimäki, A., Holli, K., Sailas, L., Kataja, V., Turpeenniemi-Hujanen, T., Isola, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2944 · Cited by 229
Breast cancer subtypes and survival in patients with brain metastases
Nam, B.-H., Kim, S. Y., Han, H.-S., Kwon, Y., Lee, K. S., Kim, T. H., & Ro, J. (2008) · Breast Cancer Research · doi:10.1186/bcr1870 · Cited by 224
Metastatic progression of breast cancer: insights from 50 years of autopsies
Cummings, M. C., Simpson, P. T., Reid, L. E., Jayanthan, J., Skerman, J., Song, S., McCart Reed, A. E., Kutasovic, J. R., Morey, A. L., Marquart, L., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4288 · Cited by 210
Pestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Láng, I., Wardley, A., Lichinitser, M., Sanchez, R. I. L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70017-2 · Cited by 210
Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Giordano, S. H., Gonzalez-Angulo, A. M., Kirshner, J. J., Krop, I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0955 · Cited by 191
Self-citationNiikura, N., Hayashi, N., Masuda, N., Takashima, S., Nakamura, R., Watanabe, K.-I., Kanbayashi, C., Ishida, M., Hozumi, Y., Tsuneizumi, M., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3090-8 · Cited by 186
Survival among women with triple receptor-negative breast cancer and brain metastases
Dawood, S., Broglio, K., Esteva, F. J., Yang, W., Kau, S.-W., Islam, R., Albarracin, C., Yu, T. K., Green, M., Hortobagyi, G. N., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn682 · Cited by 165
Metro, G., Foglietta, J., Russillo, M., Stocchi, L., Vidiri, A., Giannarelli, D., Crinò, L., Papaldo, P., Mottolese, M., Cognetti, F., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq434 · Cited by 164
Vaz-Luís, I., Ottesen, R. A., Hughes, M. E., Marcom, P. K., Moy, B., Rugo, H. S., Theriault, R. L., Wilson, J. L., Niland, J. C., Weeks, J. C., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3324 · Cited by 143
Self-citationMetastatic breast cancer subtypes and central nervous system metastases
Aversa, C., Rossi, V., Geuna, E., Martinello, R., Milani, A., Redana, S., Valabrega, G., Aglietta, M., & Montemurro, F. (2014) · The Breast · doi:10.1016/j.breast.2014.06.009 · Cited by 136
Olson, E. M., Najita, J., Sohl, J. J., Arnaout, A., Burstein, H. J., Winer, E. P., & Lin, N. (2013) · The Breast · doi:10.1016/j.breast.2012.12.006 · Cited by 128
Self-citationCancer-Specific Outcomes Among Young Adults Without Health Insurance
Aizer, A. A., Falit, B. P., Mendu, M. L., Chen, M., Choueiri, T. K., Hoffman, K. E., Hu, J. C., Martin, N. E., Trinh, Q., Alexander, B. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.2555 · Cited by 117
Self-citationPelletier, E. M., Shim, B., Goodman, S., & Amonkar, M. M. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9601-0 · Cited by 74
Hines, S. L., Vallow, L. A., Tan, W. W., McNeil, R. B., Perez, E. A., & Jain, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn283 · Cited by 65
Risk factors and survival outcomes in patients with brain metastases from breast cancer
Minisini, A. M., Moroso, S., Gerratana, L., Giangreco, M., Iacono, D., Poletto, E., Guardascione, M., Fontanella, C., Fasola, G., & Puglisi, F. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9594-5 · Cited by 41
Kuba, S., Ishida, M., Nakamura, Y., Yamanouchi, K., Minami, S., Taguchi, K., Eguchi, S., & Ohno, S. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu126 · Cited by 26
Chow, L., Suen, D. T. K., Kuen, K., & Kwong, A. (2015) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2015.03.003 · Cited by 22
Grubb, C. S., Jani, A., Wu, C., Saad, S., Qureshi, Y. H., Nanda, T., Yaeh, A. M., Rozenblat, T., Sisti, M. B., Bruce, J. N., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2014-8 · Cited by 20
Honda, Y., Aruga, T., Yamashita, T., Miyamoto, H., Horiguchi, K., Kitagawa, D., Idera, N., Goto, R., & Kuroi, K. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv067 · Cited by 15
Cited by
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,034
Tumor-Derived Extracellular Vesicles Breach the Intact Blood–Brain Barrier via Transcytosis
Morad, G., Carman, C. V., Hagedorn, E. J., Perlin, J. R., Zon, L. I., Mustafaoglu, N., Park, T.-E., Ingber, D. E., Daisy, C. C., & Moses, M. A. (2019) · ACS Nano · doi:10.1021/acsnano.9b04397 · Cited by 560
Sperduto, P. W., Mesko, S., Li, J., Cagney, D., Aizer, A., Lin, N. U., Nesbit, E., Kruser, T. J., Chan, J., Braunstein, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01255 · Cited by 471
Self-citationWang, R., Zhu, Y., Liu, X., Liao, X., He, J., & Niu, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-6311-z · Cited by 459
Epidemiology of brain metastases and leptomeningeal disease
Lamba, N., Wen, P. Y., & Aizer, A. A. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab101 · Cited by 406
Self-citation
Metadata
- Authors
- Martin, A. M., Cagney, D. N., Catalano, P. J., Warren, L. E., Bellon, J. R., Punglia, R. S., Claus, E. B., Lee, E. Q., Wen, P. Y., Haas-Kogan, D. A., Alexander, B. M., Lin, N. U., & Aizer, A. A.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-08-01
- Volume
- 3
- Issue
- 8
- Pages
- 1069
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2595711623
- Cited by
- 301
- References
- 37
- FWCI
- 20.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.